Novo Nordisk A/S
NYSE: NVO
$107.07
+$1.71 (+1.6%)
Real Time Data Delayed 15 Min.
NVO Stock Chart and Intraday Price
NVO Stock Data
| Asset Type | Common Stock |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | NOVO ALLE DK 2880, BAGSVAERD DENMARK, DK |
| Fiscal Year End | December |
| Latest Quarter | 2023-12-31 |
| Market Cap | 560,772.87M USD |
| Shares Outstanding | 4,461,910,000 |
NVO Articles
According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier were the only age cohort in the U.S. increasing their year-over-year...
Published:
The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,...
Published:
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
Published:
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who like...
Published:
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for example. Now trading at $57.80, we strongly believe it could easily rally...
Published:
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin. Undoubtedly, several investment themes, including generative AI and...
Published:
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
Published:
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
Published:
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to...
Published:
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists...
Published:
Remember when a stock becoming valued at $1 trillion was a big thing? The first company to do so was Apple (NASDAQ:AAPL) back in 2018. Now there are a half dozen trillion-dollar stocks. And while a...
Published:
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Published:
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the...
Published:
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Apple, AT&T, Cenovus Energy, Dollar General, Dynatrace, FedEx, Molson Coors Beverage, NiSource, Uber Technologies and...
Published:
Wednesday's top analyst upgrades and downgrades included Albemarle, Boeing, Ingersoll-Rand, Novo Nordisk, Nutrien, Palantir Technologies, PayPal, Shoals Technologies, Shopify, Skyworks Solutions,...
Published: